

A hand is shown in the foreground, holding a clear glass vial with a metal cap. The vial is tilted, and a small amount of liquid is visible inside. Below the hand is a white tray containing many similar glass vials, arranged in a grid. The background is slightly blurred, showing a person in a white lab coat and a blue tie. The overall scene is set in a laboratory or pharmaceutical environment.

Half-Year Financial Report H1 2026

for the period from
October 1, 2025 to March 31, 2026



Contents

Financial factsheet	3
Interim Group management report	4
Fundamental information about the Group	4
Business review of the Group	4
Report on risks and opportunities	10
Forecast report	11
Condensed interim consolidated financial statements	12
Consolidated statement of income	12
Consolidated statement of comprehensive income	13
Consolidated statement of financial position	14
Consolidated statement of cash flows	16
Consolidated statement of changes in equity	18
Notes to the condensed interim consolidated financial statements	19
Additional information	33
Responsibility statement	33
Review report	34
Supplementary information	35

Financial factsheet


H1 2026

October 1, 2025 – March 31, 2026




SCHOTT Pharma

Revenue bridge
(in EUR m)



Revenue by region
(in EUR m)



Results of operations (in EUR m)	H1 2026	H1 2025	Δ in %
Revenue	488.1	483.1	+1.0%
Share of high-value solutions (HVS)	56%	55%	-
EBITDA	129.8	130.5	-0.6%
EBITDA margin	26.6%	27.0%	-
EBIT	86.5	92.9	-6.9%
EBIT margin	17.7%	19.2%	-
Financial result	-4.1	-6.5	-36.1%
Income tax expenses	-17.9	-18.3	-2.2%
Profit for the period	64.4	68.1	-5.4%
Earnings per share (in EUR)	0.43	0.45	-4.4%


Financial position (in EUR m)	H1 2026	H1 2025
Cash flows from operating activities	95.1	72.6
Cash flows from ongoing investing activities	-49.7	-50.3
Free cash flow	45.4	22.3

Net assets (in EUR m)	Mar. 31, 2026	Sep. 30, 2025
Working capital	217.5	199.3
Working capital in % of revenue	21.9%	20.2%
Equity ratio	58.6%	55.9%
Net debt	110.0	122.2

Employees	Mar. 31, 2026	Sep. 30, 2025
Headcount (as of the reporting date)	4,839	4,811

Drug Containment Solutions (DCS)


Revenue bridge
(in EUR m)



Results of operations (in EUR m)	H1 2026	H1 2025	Δ in %
Revenue	286.4	271.1	+5.7%
EBITDA	71.8	61.3	+17.2%
EBITDA margin	25.1%	22.6%	-
EBIT	52.3	42.9	+22.1%
EBIT margin	18.3%	15.8%	-

Drug Delivery Systems (DDS)

Revenue bridge
(in EUR m)



Results of operations (in EUR m)	H1 2026	H1 2025	Δ in %
Revenue	201.8	212.2	-4.9%
EBITDA	59.5	72.5	-18.0%
EBITDA margin	29.5%	34.2%	-
EBIT	36.1	53.7	-32.9%
EBIT margin	17.9%	25.3%	-

Interim Group management report

Fundamental information about the Group

The combined management report of the annual report 2025 contains detailed information about the structure, segments, goals and strategy of SCHOTT Pharma AG & Co. KGaA, Mainz ("SCHOTT Pharma KGaA") and its subsidiaries ("SCHOTT Pharma", "SCHOTT Pharma Group" or the "Group"). As there have been no material changes to these Group fundamentals in H1 2026, the statements made there remain valid.

The SCHOTT Pharma financial year begins on October 1 and ends on September 30 of the following year. H1 2026 (previous year: H1 2025) covers the period from October 1, 2025 to March 31, 2026 (previous year: October 1, 2024 to March 31, 2025). Q2 2026 (previous year: Q2 2025) therefore relates to the period from January 1, 2026 to March 31, 2026 (previous year: January 1, 2025 to March 31, 2025).

Business review of the Group

Macroeconomic and industry environment

Most of our customers are market players in the pharma, biotech and life-science industry. They operate in largely non-cyclical growth industries. The impact of economic developments on our business is therefore limited in this respect.

Heightened geopolitical uncertainties arising from the war in the Middle East are dampening prospects for the global economy. Risks relating to the supply of energy and raw materials, as well as volatile prices, could hinder progress in curbing inflation and lead to a longer period of restrictive monetary policy. In addition, disrupted supply chains, restricted trade routes, and greater capital expenditure restraint have led to a slowdown in global economic growth. In H1 2026, the conflict had no relevant impact on the net assets, financial position or results of operations of SCHOTT Pharma.

According to analysts at the International Monetary Fund (IMF)¹, the economic conditions in the regions relevant to us have deteriorated following the outbreak of the war in the Middle East at the end of February 2026, effectively halting the previously strong growth momentum. The trade restrictions introduced in previous years continue to dampen economic activity, but have taken a back seat to geopolitical risks.

In the euro area, real GDP growth was 1.4% in 2025. The IMF expects growth to decline to 1.1% in 2026. In addition to the impact of the conflict in the Middle East, the ongoing consequences of the rise in energy prices since the Russia-Ukraine war are putting a particular strain on industry. Any upside from planned defense spending will likely take several years to materialize.

In the US, real GDP growth was 2.1% in 2025. The IMF forecasts an increase to 2.3% in 2026. As a net energy exporter, the US economy remains relatively resilient, supported by fiscal stimulus measures and the delayed effects of the key interest rate cuts in 2025. The increased trade barriers that have been in place since April 2025 continue to have a dampening effect.

China's real economic output stood at 5.0% in 2025; this is expected to slow to 4.4% in 2026. China therefore continues to grow at a significantly faster rate than Europe and the US. Domestic demand, particularly in the real estate segment, remains weak, although strong export figures have recently gone some way toward offsetting this.

¹ "World Economic Outlook: Global Economy in the Shadow of War", International Monetary Fund, April 2026."

Overall, economists are expecting global economic growth of 3.1% in 2026, after 3.4% in 2025. Growth therefore remains below the long-term historical average. Global economic activity is being constrained by heightened geopolitical risks, the fragmentation of world trade, and more restrictive financing conditions.

All in all, the general conditions for the pharma industry remain stable. The euro area will continue to be an important manufacturing location, supported by a well-established infrastructure, high regulatory standards, and a skilled workforce. However, there is a growing trend within the industry to not only further expand innovation capacities, but also to increasingly relocate production capacity to the respective sales regions. In this context, the US, which is already the world's most important pharma market, is gaining additional importance and consolidating its position as a leading center of innovation, particularly for modern biotech products. In China, however, a persistent structural duality continues to define the pharma industry: A highly price-sensitive healthcare market stands in contrast to dynamic developments in the field of pharmaceutical innovations.

Despite the geopolitical uncertainties, the market for injectable drugs showed robust structural growth of 9-10% in 2025. GLP-1 drugs in particular managed to increase their revenue share and grew significantly year-on-year. Experts from data analysis and consulting company GlobalData expect this momentum to continue in 2026 and are anticipating further growth of around 14% in the market for injectable drugs. Alongside GLP-1 drugs, complex molecules, such as monoclonal antibodies or antibody-drug conjugates (ADCs), are experiencing above average growth, underlining the structural trend toward highly effective, biologically and biotechnologically produced drugs.

The market for injectable drugs is a good indicator of general trends in demand for primary packaging. The primary packaging market relevant to SCHOTT Pharma generally mirrors the dynamics of the market for injectable drugs. However, primary packaging accounts for only part of the total cost of drugs. The growth of the market for injectable drugs is driven mainly by developments in different drug classes (biologics vs. small molecules), high-cost, specialized therapies, and high drug prices. These developments are therefore only indirectly related to the market for primary packaging and the expected performance of SCHOTT Pharma respectively.

According to IQVia Analytics, the market for primary packaging grew by around 1-2% in 2025. Growth of around 3% is expected in 2026. Most product categories for injectable drug delivery solutions continued to perform well, driven by the unabated stronger demand for biologics. Currently, over 80% of injectable drug candidates in clinical trials are biologics. This underlines the long-term positive outlook for biologics and hence our High Value Solutions. In addition, demand for delivery systems benefited from the development of new drugs in prefillable syringes as well as other drug-device combinations, designed specifically for self-administration and long-term treatments.

Results of operations

SCHOTT Pharma generated revenue of EUR 488.1m in H1 2026. This represents a year-on-year increase of 1.0% and constant currency revenue growth of 2.3%. This growth was largely driven by continued buoyant demand for High Value Solutions (HVS) in the Drug Containment Solutions segment. The HVS revenue share was up one percentage point year-on-year to 56% matching the level seen in the financial year 2025.

Revenue performance by segment

(in EUR m)	H1 2026	H1 2025 ¹	Change in %	
			Reported	Constant currencies
Drug Containment Solutions (DCS)	286.4	271.1	+5.7%	+8.3%
Drug Delivery Systems (DDS)	201.8	212.2	-4.9%	-5.4%
Consolidation/reconciliation	-0.2	-0.3	-31.1%	-31.1%
Total	488.1	483.1	+1.0%	+2.3%

¹ Adjusted information for the previous year (see note 3 in the notes to the condensed interim consolidated financial statements).

Revenue in the Drug Containment Solutions (DCS) segment was up 5.7% (at constant currencies: 8.3%), driven mainly by the change to the product mix as a result of the significant increase in demand for ready-to-use cartridges and vials, and the growth in special pharmaceutical vials. The vials have optimized inner surfaces, better geometric strength, low-friction outer coatings or special inner coatings and are therefore also particularly suitable for demanding applications.

Compared with the previous year, the Drug Delivery Systems segment (DDS) recorded a decline in revenue performance of -4.9% (at constant currencies: -5.4%). The buoyant demand for prefillable glass syringes, met in particular by the newly established manufacturing capacities in Hungary, had a positive impact. In contrast, demand for polymer syringes softened with declining sales in mRNA modalities weighing on revenue performance.

Revenue performance by region

(in EUR m)	H1 2026	H1 2025 ¹	Change in %
EMEA	276.5	242.8	+13.9%
Asia and South Pacific	75.1	87.6	-14.3%
North America	92.3	109.5	-15.8%
South America	44.2	43.2	+2.4%
Total	488.1	483.1	+1.0%

¹ Adjusted information for the previous year (see note 3 in the notes to the condensed interim consolidated financial statements).

EBITDA performance

SCHOTT Pharma's EBITDA was EUR 129.8m in H1 2026, roughly at the same level as in the previous year (EUR 130.5m). The EBITDA margin was 26.6% compared with 27.0% in the same period in the previous year.

(in EUR m)	H1 2026	H1 2025 ¹	Change in %
Drug Containment Solutions (DCS)	71.8	61.3	+17.2%
Drug Delivery Systems (DDS)	59.5	72.5	-18.0%
Consolidation/reconciliation	-1.5	-3.3	-55.3%
Total	129.8	130.5	-0.6%

¹ Adjusted information for the previous year (see note 3 in the notes to the condensed interim consolidated financial statements).

EBITDA in the DCS segment increased disproportionately to revenue performance, raising the EBITDA margin to 25.1% (H1 2025: 22.6%). Alongside volume effects, the improved product mix – driven by the increased demand for HVS products – had a particularly positive impact.

The DDS segment reported a decline in EBITDA. The EBITDA margin was 29.5% (H1 2025: 34.2%). The decline was due to a one-off impairment loss on inventories in the high single-digit million range for glass syringes. The decrease in demand for polymer syringes and the associated lower capacity utilization were also key factors. The positive revenue performance for glass syringes was only able to partially offset these effects.

In the previous year, EBITDA was impacted by negative exchange rate effects, resulting in particular from the US dollar and the Swiss franc fluctuating against the euro, and relating to the valuation of foreign exchange forward contracts. Exchange rate effects recognized in profit or loss are presented under the consolidation/reconciliation item. In the first six months of the current financial year, the impact of exchange rate fluctuations was much less significant, falling to less than half of the previous year's level.

SCHOTT Pharma consolidated statement of income

(in EUR m)	H1 2026	H1 2025 ¹	Change
Revenue	488.1	483.1	+5.0
Cost of sales	-333.2	-322.2	-11.0
Gross profit	154.9	160.9	-6.0
Selling expenses	-42.1	-42.7	+0.5
General administrative expenses	-24.1	-22.8	-1.3
Research and development costs	-13.4	-14.2	+0.9
Other operating income and expenses	3.4	4.9	-1.5
Share of profit from investments accounted for using the equity method	7.9	6.8	+1.1
Operating income (EBIT)	86.5	92.9	-6.4
Financial result	-4.1	-6.5	+2.3
Income tax expenses	-17.9	-18.3	+0.4
Profit for the period	64.4	68.1	-3.6
thereof attributable to limited liability shareholders of SCHOTT Pharma KGaA	64.2	67.8	-3.6
Earnings per share in EUR	0.43	0.45	-0.02

¹ Adjusted information for the previous year (see note 3 in the notes to the condensed interim consolidated financial statements).

The Group's cost of sales was up 3.4% and therefore slightly disproportionate to revenue. The gross profit margin was 31.7% (H1 2025: 33.3%). The decline is mainly due to the required impairment of inventories in the high single-digit million range for glass syringes as well as lower capacity utilization for polymer syringes.

The balance of other operating income and expenses was below the level in the previous year at EUR 3.4m (H1 2025: EUR 4.9m), mainly due to the year-on-year decrease in income from reimbursed costs of EUR 3.5m. This mainly includes income from research and development projects carried out for customers as well as other services provided to SCHOTT Group companies. It was offset by a reduction in exchange rate losses of EUR 1.6m, which in the previous year were primarily due to the valuation of foreign exchange forward contracts.

The financial result was up EUR 2.3m to EUR -4.1m compared to H1 2025, mainly due to lower interest expenses from cash pool financing resulting from optimization of the financing structure carried out in Q1 2026 in the form of intra-group debt restructuring.

Income tax expenses amounted to EUR -17.9m, a year-on-year decrease of EUR 0.4m. While profit before income taxes was down EUR -4.1m, the tax rate increased from 21.2 % to 21.8 % mainly due to a change in the country mix compared to the previous year – based on profit before income taxes.

The aforementioned performance resulted in a decline in profit for the period of EUR -3.6m to EUR 64.4m. Earnings per share amounted to EUR 0.43 (H1 2025: EUR 0.45).

Financial position

Equity ratio and net debt

The equity ratio of SCHOTT Pharma, calculated as the ratio of equity to total assets is monitored on an ongoing basis and was 58.6% as of March 31, 2026 (September 30, 2025: 55.9%). The higher ratio was due to a rise in equity of EUR 50.4m and a simultaneous uptick in total assets of EUR 11.4m. At EUR 64.4m, profit for the period in H1 2026 was the main factor driving the increase in equity, as well as foreign currency translation effects of EUR 10.7m and actuarial gains of EUR 2.9m in connection with changes in the interest rates relevant to the measurement of pension provisions. This was offset by dividend payments of EUR -27.6m to our limited liability shareholders and non-controlling interests. Please refer to the "Net assets" section below for more details on the increase in total assets.

SCHOTT Pharma's net debt is composed as follows:

(in EUR m)	Mar. 31, 2026	Sep. 30, 2025
Cash and cash equivalents	-27.8	-22.5
Other marketable securities	-1.3	-0.6
Fixed interest-bearing securities	-0.9	-2.6
Financial receivables – SCHOTT Group	-165.8	-155.1
Financial liabilities – SCHOTT Group	224.1	220.0
Lease liabilities	81.7	83.0
Net debt	110.0	122.2

Net debt was down on the previous year, mainly because of changes to the line items financial receivables – SCHOTT Group and financial payables – SCHOTT Group that reflect the cash pool positions vis-à-vis SCHOTT Group, as well as the change in cash and cash equivalents. The key driver here was the positive free cash flows generated, which more than offset the cash outflows resulting from dividend payments.

Statement of cash flows

(in EUR m)	H1 2026	H1 2025 ¹	Change
Cash flows from operating activities	95.1	72.6	+22.5
Cash flows from investing activities	-57.6	-50.7	-6.9
Cash flows from financing activities	-32.9	-19.0	-13.9
Net change in cash and cash equivalents	4.7	2.9	+1.8
Cash and cash equivalents at beginning of the period	22.5	23.2	-0.7
Change in cash and cash equivalents due to foreign exchange rates	0.7	0.0	+0.7
Cash and cash equivalents at end of the period	27.8	26.1	+1.7

¹Adjusted information for the previous year (see consolidated statement of cash flows).

SCHOTT Pharma posted positive cash flows from operating activities of EUR 95.1m in H1 2026 (H1 2025: EUR 72.6m). This was primarily due to operating income (EBIT) of EUR 86.5m (H1 2025: EUR 92.9m) as well as non-cash effective depreciation, amortization and impairment of non-current assets of EUR 43.3m (H1 2025: EUR 37.6m). The increase in depreciation, amortization and impairment reflects the extensive capital expenditure in capacity expansions in recent financial years. Please refer to the “Results of operations” section for details of the key drivers of EBIT performance.

Conversely, changes in working capital led to cash outflows of EUR -15.7m (H1 2025: EUR -33.6m). These were primarily due to the lower trade liabilities to third parties and to SCHOTT Group. Liabilities as of September 30, 2025 included higher liabilities relating to capital expenditure in the fourth quarter, which were settled at the beginning of the current financial year. In addition, cash outflows were attributable to the offsetting of advance payments received from customers and the resulting decrease in contract liabilities as well as to higher inventories and contract assets due to the increased volume of business. Conversely, customer payments reduced trade receivables significantly thereby having a positive effect on the change in working capital compared with the previous year.

In addition, tax payments reduced cash flows from operating activities by EUR -16.5m (H1 2025: EUR -20.9m). The balance of interest received and paid led to cash outflows of EUR -1.2m in H1 2026 (H1 2025: EUR -3.7m).

Cash flows from investing activities are broken down as follows:

(in EUR m)	H1 2026	H1 2025 ¹	Change
Cash flows from ongoing investing activities	-49.7	-50.3	+0.6
Cash flows from investment of liquid assets	-7.8	-0.5	-7.3
Cash flows from investing activities	-57.5	-50.8	-6.7

¹ Adjusted information for the previous year (see consolidated statement of cash flows).

Cash flows from ongoing investing activities include cash inflows from disposals and cash outflows for capital expenditure on property, plant and equipment and intangible assets. The balance amounted to EUR -49.7m in H1 2026, roughly at the same level as in the previous year. Capital expenditure was allocated to capacity expansion projects in both segments, particularly at the locations in Hungary and Switzerland.

Cash flows from investment of liquid assets mainly comprise changes in financial receivables – SCHOTT Group, i.e. cash pool receivables vis-à-vis SCHOTT Group. These led to cash outflows of EUR -9.1m in H1 2026 (H1 2025: EUR -0.5m), mainly due to the positive free cash flow of SCHOTT Pharma Group companies in the US and Mexico, which was invested in the SCHOTT Group as part of cash pool and treasury management.

Cash flows from financing activities led to cash outflows of EUR -32.9m in H1 2026 (H1 2025: EUR -19.0m). Significant cash outflows included dividend payments of EUR -27.1m (H1 2025: EUR -24.1m) to our limited liability shareholders and EUR -0.5m (H1 2025: EUR 0.0m) to non-controlling interests. Further cash outflows amounted to EUR -3.6m (H1 2025: EUR -5.7m) from the allocation of plan assets and EUR -1.9m (H1 2025: EUR -3.0m) from the repayment of lease liabilities. These outflows were offset by cash inflows of EUR 0.2m from the change in financial receivables – SCHOTT Group, i.e. primarily from cash pool receivables vis-à-vis SCHOTT Group, which were significantly below the previous year's figure (H1 2025: EUR 13.9m).

All in all, the increase in cash and cash equivalents was EUR 4.7m – based on the position as of the reporting date of September 30, 2025. Taking into account changes due to foreign exchange rates of EUR 0.7m, cash and cash equivalents amounted to EUR 27.8m as of March 31, 2026.

Net assets

(in EUR m)	Mar. 31, 2026	Sep. 30, 2025	Change
Non-current assets	940.8	917.2	+23.6
Current assets	669.2	681.4	-12.2
Total assets	1,610.0	1,598.6	+11.4
Equity	944.1	893.7	+50.4
Non-current liabilities	244.2	251.0	-6.8
Current liabilities	421.7	453.9	-32.2
Total equity and liabilities	1,610.0	1,598.6	+11.4

Non-current assets

Non-current assets were up EUR 23.6m to EUR 940.8m compared with September 30, 2025. This increase was mainly due to the EUR 19.2m growth in intangible assets and property, plant and equipment. Capital expenditure of EUR 50.7m was offset by depreciation and amortization of EUR 43.3m and disposals of non-current assets of EUR 0.2m. In addition, exchange rate effects of EUR 11.5m and inflationary adjustments at our Argentinian subsidiary led to an increase of EUR 0.5m. Capital expenditure was attributable mainly to the SCHOTT Pharma companies in Hungary and Switzerland, with the focus on investments relating to the expansion of manufacturing capacities in both segments. It included non-cash additions of EUR 0.6m for right-of-use assets related to leases. In addition, the overall positive performance of our joint ventures in India, Italy, and Canada led to a EUR 2.3m increase in the valuation of investments accounted for using the equity method.

Current assets

Current assets were down EUR 12.2m compared with September 30, 2025. This was largely driven by lower trade receivables from third parties and SCHOTT Group of EUR 28.9m as a result of customer payments. Conversely, financial receivables – SCHOTT Group were up EUR 10.7m, mainly due to the positive free cash flow of our Group companies in Mexico and the US. Furthermore, the higher volume of business and ongoing capacity expansions led to an increase in inventories of EUR 6.1m.

Equity

SCHOTT Pharma's equity amounted to EUR 944.1m as of the reporting date (September 30, 2025: EUR 893.7m) and the equity ratio increased from 55.9% to 58.6%. For an explanation of the increase, please refer to the elaborations on the equity ratio in the "Financial position" section.

Non-current liabilities

Non-current liabilities declined by EUR 6.8m to EUR 244.2m. Contract liabilities made a significant contribution to this decline, falling by EUR 7.7m to EUR 109.0m as a result of offsetting advance payments received from customers.

Current liabilities

Compared with September 30, 2025, current liabilities were down EUR 32.2m to EUR 421.7m. The main driver of this decrease was the reduction in trade liabilities to third parties and SCHOTT Group of EUR 33.1m. As of the previous year's reporting date, these liabilities included higher amounts related to capital expenditure in the fourth quarter, which were settled at the beginning of the current financial year. In addition, accrued liabilities were down EUR 5.1m, in particular due to the usual payments of Christmas bonuses and other bonuses to employees in the first quarter, and income tax liabilities were down EUR 6.4m due to tax payments. This was offset by an increase of EUR 4.2m in financial liabilities – SCHOTT Group, due in particular to exchange rate fluctuations as of the reporting date.

Report on risks and opportunities

Compared with the risks and opportunities detailed in the 2025 annual report, there have been the following significant developments:

The current high level of uncertainty regarding future developments and the potential medium-term global implications of military escalation in the Middle East could create risks for SCHOTT Pharma, particularly with regard to supply chain stability, energy security, and availability of materials. As of the reporting date, the risk was classified as class 2 and is being closely monitored given the continuing high volatility of the situation. The associated risk of damage is currently rated as high and the corresponding probability of occurrence as medium. Ongoing communication with customers, suppliers, and logistics service providers helps ensure that requirements, deadlines, and any necessary adjustments to the supply chains are coordinated at an early stage.

Aside from this, the risk and opportunity position has not changed significantly since September 30, 2025. Taking all planned or implemented measures into account, there were no identifiable risks at the time of reporting that would individually or collectively jeopardize SCHOTT Pharma's existence as a going concern. Further information on SCHOTT Pharma's risk management system and the risk and opportunity position can be found in the combined management report in the annual report 2025 beginning on page 39.

Forecast report

We confirm our forecast made in the annual report 2025:

Key financial performance indicator	Forecast Financial year 2026	Basis Financial year 2025
Revenue growth at constant currencies	between 2% and 5%	EUR 986.2m
EBITDA margin	around 27%	28.4%

Detailed information on the forecasts for the financial year 2026 can be found in the combined management report in the annual report 2025, beginning on page 37.

Our forecast is based on various assumptions. In terms of revenue growth, it excludes portfolio measures but assumes that exchange rates will remain constant. Furthermore, it assumes that the geopolitical and global economic situation, global supply chains, inflation and energy supply will not deteriorate, and that there will be no further relevant pandemic-related restrictions or military conflicts.

SCHOTT Pharma's actual performance may deviate positively or negatively from our forecasts, either due to the risks and opportunities described in the annual report 2025 (section entitled "Report on risks and opportunities" in the combined management report) and in the previous section, or because our expectations and assumptions fail to materialize.

Mainz, May 8, 2026

SCHOTT Pharma AG & Co. KGaA

Represented by the Management Board of SCHOTT Pharma Management AG

Dr. Christian Mias

Reinhard Mayer

Condensed interim consolidated financial statements

Consolidated statement of income

for the period from October 1, 2025 to March 31, 2026

(in EUR k)	Notes	Q2 2026	Q2 2025 ¹	H1 2026	H1 2025 ¹
Revenue	4	247,880	251,687	488,068	483,055
Cost of sales		-172,783	-168,319	-333,221	-322,214
Gross profit		75,097	83,368	154,847	160,841
Selling expenses		-20,633	-21,685	-42,104	-42,650
General administrative expenses		-11,879	-11,298	-24,136	-22,839
Research and development costs		-6,046	-7,163	-13,388	-14,237
Other operating income	5	4,540	5,328	7,253	11,361
Other operating expenses	5	-1,531	789	-3,878	-6,439
Share of profit from investments accounted for using the equity method		3,141	3,367	7,888	6,831
Operating income (EBIT)		42,689	52,706	86,482	92,868
Interest income		1,845	1,988	4,175	4,126
Interest expenses		-4,009	-4,834	-8,010	-9,636
Net other financial result	6	-212	-266	-291	-948
Financial result		-2,376	-3,112	-4,126	-6,458
Profit before income taxes		40,313	49,594	82,356	86,410
Income tax expenses	7	-9,174	-11,304	-17,936	-18,340
Profit for the period		31,139	38,290	64,420	68,070
thereof attributable to non-controlling interests	10	126	153	227	244
thereof attributable to limited liability shareholders of SCHOTT Pharma KGaA		31,013	38,137	64,193	67,826
Earnings per share (in EUR), based on the share of profit for the period attributable to limited liability shareholders of SCHOTT Pharma KGaA					
Basic		0.21	0.25	0.43	0.45
Diluted		0.21	0.25	0.43	0.45

¹ Adjusted information for the previous year (see note 3).

Consolidated statement of comprehensive income

for the period from October 1, 2025 to March 31, 2026

(in EUR k)	Q2 2026	Q2 2025 ¹	H1 2026	H1 2025 ¹
Profit for the period	31,139	38,290	64,420	68,070
Actuarial gains/losses from pension provisions	253	5,004	3,381	4,220
Deferred taxes	-154	-884	-511	-830
Items that will not be reclassified to the consolidated statement of income in future periods	99	4,120	2,870	3,390
Foreign currency translation differences	10,551	-8,904	13,860	-1,461
Foreign currency translation differences attributable to non-controlling interests	88	19	170	54
Foreign currency translation differences from investments accounted for using the equity method	-2,485	-2,507	-3,356	1,083
Items that will be reclassified to the consolidated statement of income in future periods	8,154	-11,392	10,674	-324
Other comprehensive income	8,253	-7,272	13,544	3,066
Total comprehensive income	39,392	31,018	77,964	71,136
thereof attributable to non-controlling interests	214	172	397	298
thereof attributable to limited liability shareholders of SCHOTT Pharma KGaA	39,178	30,846	77,567	70,838

¹ Adjusted information for the previous year (see note 3).

Consolidated statement of financial position

as of March 31, 2026

Assets

(in EUR k)	Notes	Mar. 31, 2026	Sep. 30, 2025
Intangible assets		30,403	29,689
Property, plant and equipment	8	804,142	785,673
Investments accounted for using the equity method		90,780	88,498
Deferred tax assets		15,384	13,042
Other financial assets		24	1
Other non-financial assets		87	342
Non-current assets		940,820	917,245
Inventories	9	181,067	174,975
Contract assets		84,393	79,746
Trade receivables		166,735	195,263
Trade receivables – SCHOTT Group	14	5,676	6,095
Financial receivables – SCHOTT Group	14	165,817	155,103
Income tax assets		5,049	10,458
Other financial assets		8,268	11,396
Other non-financial assets		24,400	25,895
Cash and cash equivalents		27,813	22,470
Current assets		669,218	681,401
Total assets		1,610,038	1,598,646

Equity and liabilities

(in EUR k)	Notes	Mar. 31, 2026	Sep. 30, 2025
Subscribed capital	10	150,615	150,615
Capital reserves	10	494,481	494,481
Retained earnings	10	319,739	279,787
Other reserves	10	-22,596	-33,100
Equity attributable to limited liability shareholders of SCHOTT Pharma KGaA		942,239	891,783
Non-controlling interests	10	1,899	1,966
Equity		944,138	893,749
Provisions for pensions and similar commitments		20,670	23,573
Provisions for income taxes		7,950	2,902
Other provisions		6,250	6,656
Deferred tax liabilities		22,650	21,989
Contract liabilities		108,963	116,700
Other financial liabilities		77,709	79,226
Non-current liabilities		244,192	251,046
Other provisions		10,253	9,917
Accrued liabilities		44,007	49,076
Contract liabilities		28,120	26,314
Trade liabilities		48,766	73,305
Trade liabilities – SCHOTT Group	14	21,996	30,574
Financial liabilities – SCHOTT Group	14	224,134	219,953
Income tax liabilities		16,057	22,498
Other financial liabilities		10,654	6,371
Other non-financial liabilities		17,721	15,843
Current liabilities		421,708	453,851
Total equity and liabilities		1,610,038	1,598,646

Consolidated statement of cash flows

for the period from October 1, 2025 to March 31, 2026

(in EUR k)	Notes	H1 2026	H1 2025 ^{1,2}
Profit for the period		64,420	68,070
Depreciation, amortization and impairment as well as impairment reversals on non-current assets		43,277	37,621
Changes in provisions and accrued liabilities		2,969	25
Other non-cash income/expenses		-8,189	-4,083
Net gain or loss on the disposal of intangible assets and property, plant and equipment		-120	-151
Net gain or loss from financial assets		-193	-631
Changes in inventories and advance payments made on inventories	9	-2,247	-15,724
Changes in contract assets		-4,647	-19,285
Changes in trade receivables		32,694	-578
Changes in trade receivables – SCHOTT Group	14	637	666
Changes in other assets		12,166	10,808
Changes in contract liabilities		-7,773	16,555
Changes in trade liabilities		-25,362	-15,915
Changes in trade liabilities – SCHOTT Group	14	-9,024	650
Changes in other liabilities		-1,186	-4,090
Changes in deferred taxes	7	-2,302	-1,357
Cash flows from operating activities (A)		95,120	72,581
Cash inflows from the sale of property, plant and equipment	8	374	738
Purchase of property, plant and equipment	8	-50,030	-50,935
Purchase of intangible assets		-74	-75
Cash flows from ongoing investing activities		-49,730	-50,272
Cash inflows from the sale of financial assets		1,751	0
Purchase of financial assets		-477	0
Changes in financial receivables – SCHOTT Group	14	-9,110	-473
Cash flows from investing activities (B)		-57,566	-50,745
Dividends paid to limited liability shareholders	10	-27,111	-24,098
Dividends paid to non-controlling interests		-464	0
Changes in financial liabilities – SCHOTT Group	14	150	13,889
Cash outflows from allocation to plan assets		-3,573	-5,749
Cash outflows from repayments of outstanding lease liabilities		-1,885	-3,000
Cash flows from financing activities (C)		-32,883	-18,958

(in EUR k)	Notes	H1 2026	H1 2025
Net change in cash and cash equivalents (A+B+C)		4,671	2,878
Cash and cash equivalents at beginning of the period		22,470	23,182
- Cash on hand		1	3
- Bank deposits		22,469	23,179
Change in cash and cash equivalents due to foreign exchange rates		672	31
Cash and cash equivalents at end of the period		27,813	26,091
- Cash on hand		4	4
- Bank deposits		27,809	26,087
Additional notes to the consolidated statement of cash flows³			
Interest paid		-5,381	-7,850
Interest received		4,175	4,126
Income tax expenses paid		-16,495	-20,931

¹ Adjusted information for the previous year (see note 3).

² Adjusted information for the previous year – reclassifications from cash flows from financing activities: the item change in financial receivables – SCHOTT Group has been reported within cash flows from investing activities since the financial year 2025. Previously, allocation to cash flows from financing activities was based on an economic perspective, deviating from the provisions of IAS 7.16. A legal approach as set out in IAS 32.42 will be applied going forward. As a result, cash flows from investing activities were down EUR -473k. In addition, cash flows related to financial assets and financial liabilities have been reclassified and from this point forward will be allocated to cash flows from operating activities. This led to an increase in cash flows from operating activities of EUR 174k. Cash flows from financing activities increased by a total of EUR 299k. Additional details are provided in note 33 of the notes to the consolidated financial statements in the annual report 2025.

³ Included in cash flows from operating activities.

Consolidated statement of changes in equity

for the period from October 1, 2025 to March 31, 2026

(in EUR k)	Subscribed capital	Capital reserves	Retained earnings	Other reserves	Equity attributable to limited liability shareholders of SCHOTT Pharma KGaA	Non-controlling interests	Group equity
Oct. 1, 2024¹	150,615	494,481	154,705	-13,173	786,628	1,863	788,491
Profit for the period ²	0	0	67,826	0	67,826	244	68,070
Other comprehensive income	0	0	3,390	-378	3,012	54	3,066
Total comprehensive income	0	0	71,216	-378	70,838	298	71,136
Dividends	0	0	-24,098	0	-24,098	0	-24,098
Mar. 31, 2025	150,615	494,481	201,823	-13,551	833,368	2,161	835,529
Oct. 1, 2025	150,615	494,481	279,787	-33,100	891,783	1,966	893,749
Profit for the period	0	0	64,193	0	64,193	227	64,420
Other comprehensive income	0	0	2,870	10,504	13,374	170	13,544
Total comprehensive income	0	0	67,063	10,504	77,567	397	77,964
Dividends ³	0	0	-27,111	0	-27,111	-464	-27,575
Mar. 31, 2026	150,615	494,481	319,739	-22,596	942,239	1,899	944,138

¹ Adjusted information for the previous year (see note 3.5 in the notes to the consolidated financial statements in the annual report 2025).

² Adjusted information for the previous year (see note 3).

³ For further information, please refer to note 10.

Notes to the condensed interim consolidated financial statements

for the period from October 1, 2025 to March 31, 2026

General disclosures

1 Preliminary remarks

SCHOTT Pharma AG & Co. KGaA, Mainz ("SCHOTT Pharma KGaA" or the "Company") is a listed partnership limited by shares under German law. The shares of SCHOTT Pharma KGaA are admitted to trading on the Regulated Market of the Frankfurt Stock Exchange and simultaneously admitted to the sub-segment of the Frankfurt Stock Exchange's Regulated Market with additional post-admission listing obligations (Prime Standard). The shares are listed with the ticker symbol 1SXP and ISIN DE000A3ENQ51.

The condensed interim consolidated financial statements reflect the business activities of SCHOTT Pharma KGaA and its subsidiaries ("SCHOTT Pharma", "SCHOTT Pharma Group" or the "Group"). SCHOTT Pharma Group is a leading global supplier of high-quality pharmaceutical packaging. The portfolio comprises drug containment and delivery systems such as prefillable syringes made of glass and polymer, cartridges, vials, and ampoules.

SCHOTT Pharma KGaA has its registered office at Hattenbergstrasse 10, 55122 Mainz, Germany, and is entered in the commercial register of the local court in Mainz under HRB 51230. The Company's general partner is SCHOTT Pharma Management AG, Mainz, Germany ("SCHOTT Pharma Management AG").

The majority limited partner of SCHOTT Pharma KGaA and the sole shareholder of SCHOTT Pharma Management AG is SCHOTT Glaswerke Beteiligungs- und Export GmbH, based in Mainz. Its sole shareholder is SCHOTT AG, based in Mainz (SCHOTT AG). The Carl Zeiss Foundation, Heidenheim an der Brenz and Jena, Germany, is the sole shareholder of SCHOTT AG. As the ultimate parent company, SCHOTT AG prepares consolidated financial statements for the largest group of consolidated companies, in which SCHOTT Pharma KGaA is included. SCHOTT AG and its subsidiaries are referred to in the following as "SCHOTT Group".

The condensed interim consolidated financial statements (hereinafter "interim consolidated financial statements") of SCHOTT Pharma KGaA were prepared on a going concern basis and in accordance with section 115 of the German Securities Trading Act (Wertpapierhandelsgesetz, WpHG) and IAS 34 Interim Financial Reporting. They comply with the International Financial Reporting Standards (IFRS) published by the International Accounting Standards Board (IASB), London, in the version adopted by the European Union.

The interim consolidated financial statements are prepared in euros. Unless stated otherwise, all amounts are shown in thousands of euros (EUR k). Both individual and total values represent the figure with the smallest rounding difference. This means that minor differences may occur between the sums reported and the sum total of the individual figures shown. The consolidated statement of income has been prepared using the cost of sales (function of expense) method.

The results presented in the interim consolidated financial statements are not necessarily indicative of results that can be expected in future periods or are to be expected for the entire financial year.

The SCHOTT Pharma financial year begins on October 1 and ends on September 30 of the following year. H1 2026 (previous year: H1 2025) covers the period from October 1, 2025 to March 31, 2026 (previous year: October 1, 2024 to March 31, 2025). Q2 2026 (previous year: Q2 2025) therefore relates to the period from January 1, 2026 to March 31, 2026 (previous year: January 1, 2025 to March 31, 2025).

The interim consolidated financial statements were prepared by the Management Board on May 8, 2026 and released to be submitted to the Supervisory Board. The interim consolidated financial statements were reviewed by the Group's external auditors in accordance with section 115(5) of the German Securities Trading Act (Wertpapierhandelsgesetz, WpHG) and are published on the Company's website.

2 Changes in accounting standards and application of new and revised accounting standards

Standards and interpretations to be applied in the current financial year

The International Accounting Standards Board (IASB) published the following new and amended standards and interpretations which are to be applied for the first time in the financial year 2026.

Standards		Mandatory application in financial years beginning on or after	Amended/ supplementary disclosures in the notes
IAS 21	Amendments to IAS 21: Lack of Exchangeability	Jan. 1, 2025	No

The published new and amended standards and interpretations, which will be applicable for the first time in the financial year 2026, currently have no significant impact on the presentation of SCHOTT Pharma's net assets, financial position and results of operations. However, they might influence reporting of future transactions.

Published standards and interpretations that have not yet been applied

Besides the mandatory new and amended standards and interpretations referred to above, the IASB published other IFRS that have already been endorsed by the EU in part, but will only become mandatory at a later date.

Standards		Mandatory application in financial years beginning on or after	Adoption by the European Commission
IFRS 9 and IFRS 7	Amendments to IFRS 9 and IFRS 7: Classification and Measurement of Financial Instruments	Jan. 1, 2026	May 27, 2025
IFRS 9 and IFRS 7	Amendments to IFRS 9 and IFRS 7: Contracts Referencing Nature-dependent Electricity	Jan. 1, 2026	Jun. 30, 2025
IFRS 1, IFRS 7, IFRS 9, IFRS 10 and IAS 7	Annual Improvements to IFRS Accounting Standards – Volume 11	Jan. 1, 2026	Jul. 9, 2025
IFRS 18	Presentation and Disclosure in Financial Statements	Jan. 1, 2027	Feb. 13, 2026
IFRS 19	Subsidiaries without Public Accountability: Disclosures	Jan. 1, 2027	No
IAS 21	Amendments to IAS 21: The Effects of Changes in Foreign Exchange Rates: Translation to a Hyperinflationary Presentation Currency	Jan. 1, 2027	No
IFRS 19	Amendments to IFRS 19: Subsidiaries without Public Accountability: Disclosures	Jan. 1, 2027	No

IFRS 18: Presentation and Disclosure in Financial Statements

IFRS 18 Presentation and Disclosure in Financial Statements was issued by the IASB on April 9, 2024. IFRS 18 affects all financial statements prepared in accordance with IFRS and includes new fundamental requirements for how companies present and disclose financial performance in the primary financial statements and the notes. IFRS 18 introduces two new defined subtotals and categories for classifying income and expenses, enhanced guidance for grouping (aggregation and disaggregation) of information, disclosures on management-defined performance measures in the notes and specific improvements to the statement of cash flows by amending IAS 7 Cash Flow Statement. Application for the first time is currently planned for financial years beginning on or after January 1, 2027, and initial application must be retrospective. SCHOTT Pharma does not make use of the existing option for early adoption. SCHOTT Pharma is currently assessing the impact that initial application of IFRS 18 will have on the Company's consolidated financial statements.

Regarding the other standards, SCHOTT Pharma also does not make use of any existing options for early adoption. These standards will be implemented in the consolidated financial statements as of the date of mandatory adoption. According to current assessments, the other new and amended regulations have no material effect on SCHOTT Pharma's net assets, financial position and results of operations.

3 Significant accounting policies and methods of consolidation

Unless otherwise specified, the interim consolidated financial statements were prepared on the basis of the accounting policies of the audited and published consolidated financial statements of SCHOTT Pharma KGaA as of September 30, 2025 and should be read in conjunction with them.

In the management's opinion, the interim consolidated financial statements contain all adjustments (i.e. customary adjustments to be made on an ongoing basis) that are necessary to appropriately present the Group's net assets, financial position and results of operations. All significant intra-group balances and transactions have been eliminated.

Scope of consolidation

Along with SCHOTT Pharma KGaA, one additional consolidated company (previous year: one) based in Germany and 14 foreign consolidated companies (previous year: 14) were fully included in the interim consolidated financial statements. Subsidiaries are included using the full consolidation method from the date on which SCHOTT Pharma KGaA obtains control. SCHOTT Pharma KGaA is deemed to have control if it is exposed or has rights to variable returns from its involvement in the Company and can affect those returns through its power over the Company. Three companies (previous year: three) were accounted for using the equity method in the interim consolidated financial statements.

No acquisitions, divestments or other changes in the scope of consolidation took place in the first half of the financial year 2026. A statement of the SCHOTT Pharma Group's shareholdings in accordance with section 313(2) of the German Commercial Code (Handelsgesetzbuch, HGB) can be found in note 3.1 of the notes to the consolidated financial statements in the annual report 2025.

Income tax expenses

For the purposes of calculating the tax expense, the rule set out in IAS 34.30c applies. Income taxes are recognized on the basis of the best estimate of the weighted average annual income tax rate expected for the full financial year.

Adjustment of previous year's information

A retrospective adjustment was made to revenue, cost of sales and income tax expenses in the consolidated income statement and the consolidated statement of comprehensive income, in each case for the period from October 1, 2024 to March 31, 2025, as certain products were included in revenue recognized over time, although the requirements in accordance with IFRS 15.35(c) were not met in full. Additional details are provided in note 3.5 of the notes to the consolidated financial statements in the annual report 2025.

As a result of the adjustment, revenue rose by EUR 888k in H1 2025, cost of sales by EUR -330k, and income tax expenses by EUR -67k. In turn, EBIT and EBITDA also rose by EUR 558k, and Group profit for the period and total comprehensive income each rose by EUR 491k. There were no material impacts on diluted and undiluted earnings per share, the EBITDA margin or revenue growth.

In the cash flows from operating activities item in the consolidated statement of cash flows, the adjustment also resulted in reclassifications between individual line items in H1 2025, without this having an impact on the total cash flows from operating activities.

Furthermore, the adjustments also affected the consolidated statement of changes in equity as well as the disclosures on revenue (note 4) and segment reporting (note 13).

Notes to the consolidated statement of income and the consolidated statement of financial position

4 Revenue

Revenue mainly results from the sale of goods.

Revenue is presented by segment and region as part of segment reporting in note 13.

Sales revenue can also be divided according to standard (core) and premium solutions (high-value solutions, HVS):

(in EUR k)	H1 2026	H1 2025 ¹
High-value solutions (HVS)	272,987	266,629
of which DCS	71,141	54,387
of which DDS	201,846	212,242
Core	215,081	216,426
of which DCS	215,081	216,426
of which DDS	0	0
Total	488,068	483,055

¹ Adjusted information for the previous year (see note 3).

5 Other operating income and expenses

The balance of other operating income and expenses of EUR 3,375k was down year-on-year (H1 2025: EUR 4,922k). The main reason for this was the EUR 3,481k decrease in income from reimbursed costs. This mainly includes income from research and development projects carried out for customers as well as income from other services provided to SCHOTT Group companies. A positive factor was the year-on-year reduction in exchange rate losses of EUR 1,632k, which in the previous year were primarily due to the valuation of foreign exchange forward contracts.

In the current half-year, SCHOTT Pharma received government grants of EUR 327 k (H1 2025: EUR 926k), for which the conditions for recognition have been definitively met.

Exchange rate losses of EUR 11,490k (H1 2025: EUR 11,719k) are netted against exchange rate gains of EUR 10,703k (H1 2025: EUR 9,300k). The balance in H1 2026 amounted to EUR -787k (H1 2025: EUR -2,419k) and is presented under other operating expenses.

6 Other financial result

The functional currency of SCHOTT Envases Argentina S.A., Buenos Aires, Argentina, which is included in the interim consolidated financial statements – i.e. the Argentine peso – is considered to be hyperinflationary within the meaning of IAS 29 Financial Reporting in Hyperinflationary Economies. A general price index that reflects the changes in purchasing power must be determined for the restatement. This index should be applied by all companies reporting in the currency of this economy. SCHOTT Pharma applies the indices proposed by the Federación Argentina de Consejos Profesionales de Ciencias Económicas (FACPCE) in Resolution JG 539/18, which companies using the Argentine peso as their functional currency should apply to determine any restatement required due to hyperinflation. The index stood at 1.18 as of March 31, 2026 (September 30, 2025: 1.32; March 31, 2025: 1.16).

Net gains or losses from current changes in inflation rates reflect the effects of restatements of non-monetary assets, equity and items of the statement of income following changes in purchasing power. In H1 2026, SCHOTT Pharma realized inflation-related losses of EUR 483k due to the decline in purchasing power (H1 2025: EUR 1,604k).

7 Income tax expenses

In H1 2026, the tax rate rose to 21.8% (H1 2025: 21.2%), mainly due to a change in the country mix compared to the previous year – based on profit before income taxes.

The application of the rules on global minimum taxation (Pillar Two) resulted in a tax expense for qualified domestic top-up taxes for SCHOTT Pharma of EUR 642k in H1 2026 (H1 2025: EUR 419k).

8 Property, plant and equipment

(in EUR k)	Land, land rights and buildings	Technical equipment and machinery	Other equipment, operating and office equipment	Assets under construction	Total
Cost					
Oct. 1, 2024	336,466	580,568	149,977	192,490	1,259,501
Additions	1,461	3,989	2,385	44,286	52,121
Disposals	175	6,912	1,060	0	8,147
Reclassifications	8,589	41,813	6,462	-56,891	-27
Hyperinflation adjustment	893	1,459	275	-1,031	1,596
Foreign currency translation	-1,648	-2,621	-1,011	-1,079	-6,359
Mar. 31, 2025	345,586	618,296	157,028	177,775	1,298,685
Accumulated depreciation and impairment					
Oct. 1, 2024	110,985	327,358	97,413	255	536,011
Depreciation and impairment ¹	8,641	20,984	7,692	41	37,358
Disposals	166	6,478	899	0	7,543
Reclassifications	47	17	7	-71	0
Hyperinflation adjustment	1,135	1,178	265	0	2,578
Foreign currency translation	-810	-1,561	-610	26	-2,955
Mar. 31, 2025	119,832	341,498	103,868	251	565,449
Carrying amount					
Mar. 31, 2025	225,754	276,798	53,160	177,524	733,236
Cost					
Oct. 1, 2025	357,499	646,467	165,878	205,073	1,374,917
Additions	542	4,957	746	44,382	50,627
Disposals	233	15,796	1,903	0	17,932
Reclassifications	8,370	29,213	3,379	-40,943	19
Hyperinflation adjustment	443	1,311	167	42	1,963
Foreign currency translation	5,034	9,976	2,352	2,740	20,102
Mar. 31, 2026	371,655	676,128	170,619	211,294	1,429,696
Accumulated depreciation and impairment					
Oct. 1, 2025	126,636	353,672	108,567	369	589,244
Depreciation and impairment ¹	9,851	23,858	9,110	228	43,047
Disposals	214	15,648	1,817	0	17,679
Reclassifications	10	2,454	-2,306	-153	5
Hyperinflation adjustment	357	1,214	149	0	1,720
Foreign currency translation	1,930	5,660	1,620	7	9,217
Mar. 31, 2026	138,570	371,210	115,323	451	625,554
Carrying amount					
Mar. 31, 2026	233,085	304,918	55,296	210,843	804,142

¹ Impairment losses are included in depreciation and impairment.

In H1 2026, there were major additions related to the expansion of manufacturing locations in Hungary and Switzerland, also resulting in the reclassification of assets under construction.

9 Inventories

In H1 2026, impairment losses to write down inventories to their net realizable value in the amount of EUR 12,251k (H1 2025: EUR 6,852k) were recognized. Included were a one-off impairment loss on inventories in the

high single-digit million range for glass syringes as well as reversals of impairment losses due to changes in estimates of future sales volumes amounting to EUR 138k (H1 2025: EUR 1,039k).

10 Equity

As of March 31, 2026, the subscribed capital of SCHOTT Pharma KGaA amounted to EUR 150,615k, which is unchanged as against the previous year and is fully paid in as of the reporting date. Subscribed capital consists of 150,614,616 ordinary bearer shares with no-par value and a notional interest of EUR 1.00 each in the share capital. As no new ordinary bearer shares were issued in H1 2026, the number of outstanding shares has not changed compared with the previous year. Each share grants the holder one voting right at the Annual general meeting and entitles them to receive dividends if a resolution is passed to this effect.

The annual general meeting on February 3, 2026 resolved to distribute a dividend of EUR 0.18 per no-par value share for the financial year 2025. The distribution was made on February 6, 2026. This corresponds to a dividend distribution of EUR 27,111k. as of the reporting date. The remaining net retained profit reported in the annual financial statements of SCHOTT Pharma KGaA has been carried forward to new account.

Non-controlling interests

Non-controlling interests reported in the interim consolidated financial statements relate to shares held by other shareholders in SCHOTT Envases Farmacéuticos SAS, Bogotá, Colombia.

Additional notes

11 Financial instruments

The following tables outline the carrying amounts and fair values by measurement categories and classes of financial instruments as of March 31, 2026 and September 30, 2025.

Classifications and fair values as of March 31, 2026

Measurement category			Financial assets measured at amortized cost (AC)		Financial assets measured at fair value through profit or loss (FVTPL)			
Class			Loans, receivables and fixed interest-bearing securities		Securities and derivatives		Financial assets not within the scope of IFRS 7	
Items in the consolidated statement of financial position (in EUR k)	Carrying amounts Total	Fair values Total	Carrying amount	Fair value	Carrying amount	Fair value	Carrying amount	Fair value ¹
Assets								
Non-current assets								
Investments accounted for using the equity method	90,780	n/a ²	0	0	0	0	90,780	n/a ²
Other financial assets	24	24	24	24	0	0	0	0
Current assets								
Trade receivables	166,735	166,735	166,735	166,735	0	0	0	0
Trade receivables – SCHOTT Group	5,676	5,676	5,676	5,676	0	0	0	0
Financial receivables – SCHOTT Group	165,817	165,817	165,817	165,817	0	0	0	0
Other financial assets	8,268	8,771	3,732	4,235	4,536	4,536	0	0
Cash and cash equivalents	27,813	27,813	27,813	27,813	0	0	0	0
Total	465,113	374,836	369,797	370,300	4,536	4,536	90,780	0
Measurement category			Financial liabilities measured at amortized cost (AC)				Financial liabilities measured at fair value through profit or loss (FVTPL)	
Class			Liabilities		Lease liabilities		Derivatives	
Items in the consolidated statement of financial position (in EUR k)	Carrying amounts Total	Fair values Total	Carrying amount	Fair value	Carrying amount	Fair value ³	Carrying amount	Fair value
Equity and liabilities								
Non-current liabilities								
Other financial liabilities	77,709	9	9	9	77,700	n/a ²	0	0
Current liabilities								
Accrued liabilities	17,716	17,716	17,716	17,716	0	0	0	0
Trade liabilities	48,766	48,766	48,766	48,766	0	0	0	0
Trade liabilities – SCHOTT Group	21,996	21,996	21,996	21,996	0	0	0	0
Financial liabilities – SCHOTT Group	224,134	224,134	224,134	224,134	0	0	0	0
Other financial liabilities	10,654	6,656	3,977	3,977	3,998	n/a ²	2,679	2,679
Total	400,975	319,277	316,598	316,598	81,698	0	2,679	2,679

¹ SCHOTT Pharma's investments in associates and joint ventures accounted for using the equity method are not within the scope of IFRS 7 Financial Instruments: Disclosures.

² Not applicable.

³ Lease liabilities according to IFRS 16 Leases do not fall within the scope of IFRS 9 Financial Instruments, thus their fair values do not have to be determined and disclosed.

Classifications and fair values as of September 30, 2025

Measurement category	Financial assets measured at amortized cost (AC)				Financial assets measured at fair value through profit or loss (FVTPL)			
	Carrying amounts		Fair values		Carrying amounts		Fair values	
Class	Loans, receivables and fixed interest-bearing securities				Securities and derivatives		Financial assets not within the scope of IFRS 7	
Items in the consolidated statement of financial position (in EUR k)	Carrying amounts Total	Fair values Total	Carrying amount	Fair value	Carrying amount	Fair value	Carrying amount	Fair value ¹
Assets								
Non-current assets								
Investments accounted for using the equity method	88,498	n/a ²	0	0	0	0	88,498	n/a ²
Other financial assets	1	1	1	1	0	0	0	0
Current assets								
Trade receivables	195,263	195,263	195,263	195,263	0	0	0	0
Trade receivables – SCHOTT Group	6,095	6,095	6,095	6,095	0	0	0	0
Financial receivables – SCHOTT Group	155,103	155,103	155,103	155,103	0	0	0	0
Other financial assets	11,396	11,730	4,811	5,145	6,585	6,585	0	0
Cash and cash equivalents	22,470	22,470	22,470	22,470	0	0	0	0
Total	478,826	390,662	383,743	384,077	6,585	6,585	88,498	0
Measurement category	Financial liabilities measured at amortized cost (AC)						Financial liabilities measured at fair value through profit or loss (FVTPL)	
Class	Carrying amounts		Fair values		Lease liabilities		Derivatives	
Items in the consolidated statement of financial position (in EUR k)	Carrying amounts Total	Fair values Total	Carrying amount	Fair value	Carrying amount	Fair value ³	Carrying amount	Fair value
Equity and liabilities								
Non-current liabilities								
Other financial liabilities	79,226	23	23	23	79,203	n/a ²	0	0
Current liabilities								
Accrued liabilities	15,645	15,645	15,645	15,645	0	0	0	0
Trade liabilities	73,305	73,305	73,305	73,305	0	0	0	0
Trade liabilities – SCHOTT Group	30,574	30,574	30,574	30,574	0	0	0	0
Financial liabilities – SCHOTT Group	219,953	219,953	219,953	219,953	0	0	0	0
Other financial liabilities	6,371	2,560	700	700	3,811	n/a ²	1,860	1,860
Total	425,074	342,060	340,200	340,200	83,014	0	1,860	1,860

¹ SCHOTT Pharma's investments in associates and joint ventures accounted for using the equity method are not within the scope of IFRS 7 Financial Instruments: Disclosures.

² Not applicable.

³ Lease liabilities according to IFRS 16 Leases do not fall within the scope of IFRS 9 Financial Instruments, thus their fair values do not have to be determined and disclosed.

Other current financial assets include positive market values of derivatives in the amount of EUR 3,276k (September 30, 2025: EUR 5,994k). Other current financial liabilities include negative market values of derivatives in the amount of EUR 2,679k (September 30, 2025: EUR 1,860k).

Fair value measurement

For financial assets and financial liabilities measured at fair value through profit or loss (FVTPL), the fair value of derivatives is measured using significant observable input parameters (spot prices and yield curves), while the fair value of securities is measured using quoted prices on active markets. Accordingly, derivatives are assigned to Level 2 in the fair value hierarchy. Securities are assigned to Level 1.

There were no reclassifications between the levels of the fair value hierarchy in the current period.

12 Other financial obligations

Purchase commitments for non-current assets amount to EUR 89,581k as of the reporting date (September 30, 2025: EUR 128,008k).

13 Segment reporting

In accordance with IFRS 8 Operating Segments, segment reporting is presented on the basis of the internal management and reporting system for the Management Board of SCHOTT Pharma. The Management Board is the Chief Operating Decision Maker (CODM) as defined in IFRS 8 Operating Segments and monitors the operating results of its operating segments separately for the purpose of making decisions about resource allocation and performance assessment. The definition of the operating segments as well as the indicators described are in line with internal management and reporting; the key performance indicators are revenue and EBITDA, as well as the EBITDA margin derived from these figures. The accounting and financial reporting principles applied are the same as those described for SCHOTT Pharma Group in note 3.6 of the notes to the consolidated financial statements in the annual report 2025.

SCHOTT Pharma comprises the two operating segments Drug Containment Solutions (DCS) and Drug Delivery Systems (DDS). Additional information on the operating segments can be found in note 37 of the notes to the consolidated financial statements and in the "Segments" section in the combined management report in the annual report 2025.

The business relationships between the operating segments are generally based on prices that are also agreed upon with third parties. Revenue and further transactions between operating segments are eliminated upon consolidation and presented in the consolidation/reconciliation column. The consolidation/reconciliation column also includes the necessary reconciliation and reclassification items, plus exchange rate effects recognized in profit or loss. In addition, all assets and liabilities of SCHOTT Pharma that do not meet the definition of segment assets and segment liabilities are presented in the consolidation/reconciliation column. Capital expenditure shown in the consolidation/reconciliation column refers to investments made by headquarters.

(in EUR k)	H1 2026			
	DCS	DDS	Consolidation/ reconciliation	Total
External revenue	286,222	201,846	0	488,068
Inter-segment revenue	184	2	-186	0
Cost of sales	194,068	139,206	-53	333,221
Reversals of impairment losses/impairment losses	0	761	0	761
Share of profit from investments accounted for using the equity method	5,849	2,039	0	7,888
Operating income (EBIT)	52,325	36,056	-1,899	86,482
Depreciation, amortization and impairment	19,456	23,395	426	43,277
EBITDA	71,781	59,451	-1,474	129,758
Reconciliation from segment EBITDA to SCHOTT Pharma profit for the period:				
Depreciation, amortization and impairment				-43,277
Financial result				-4,126
Income tax expenses				-17,936
Profit for the period				64,420
Capital expenditure	26,710	23,334	60	50,104
Segment assets ¹	205,189	227,972	1,176,877	1,610,038
Segment liabilities ¹	104,175	103,562	458,163	665,900

¹ As of the reporting date of March 31, 2026.

(in EUR k)	H1 2025 ¹			
	DCS	DDS	Consolidation/ reconciliation	Total
External revenue	270,813	212,242	0	483,055
Inter-segment revenue	264	2	-266	0
Cost of sales	192,230	129,249	735	322,214
Reversals of impairment losses/impairment losses	0	0	0	0
Share of profit from investments accounted for using the equity method	5,266	1,565	0	6,831
Operating income (EBIT)	42,865	53,714	-3,711	92,868
Depreciation, amortization and impairment	18,407	18,793	421	37,621
EBITDA	61,272	72,507	-3,290	130,489
Reconciliation from segment EBITDA to SCHOTT Pharma profit for the period:				
Depreciation, amortization and impairment	-	-	-	-37,621
Financial result	-	-	-	-6,458
Income tax expenses	-	-	-	-18,340
Profit for the period	-	-	-	68,070
Capital expenditure	25,561	25,034	415	51,010
Segment assets ²	195,326	256,457	1,146,863	1,598,646
Segment liabilities ²	110,865	131,089	462,943	704,897

¹ Adjusted information for the previous year (see note 3).

² As of the reporting date of September 30, 2025.

The geographical information is based on the geographical regions of Europe, the Middle East, Africa (EMEA), Asia and the South Pacific, North America, and South America. Revenue presented in the tables below refers to revenue generated within the first six months of a financial year, while non-current assets are reported as of the respective reporting date.

(in EUR k)	H1 2026				
	EMEA	Asia and South Pacific	North America	South America	Total
Revenue by location of the customer	276,521	75,092	92,252	44,203	488,068
Revenue by location of the company	327,771	51,465	65,653	43,179	488,068
Non-current assets ¹	684,282	143,102	70,134	27,894	925,412

¹ As of the reporting date of March 31, 2026.

(in EUR k)	H1 2025 ¹				
	EMEA	Asia and South Pacific	North America	South America	Total
Revenue by location of the customer	242,764	87,623	109,518	43,150	483,055
Revenue by location of the company	305,433	59,717	75,478	42,427	483,055
Non-current assets ²	668,959	137,933	70,686	26,624	904,202

¹ Adjusted information for the previous year (see note 3).

² As of the reporting date of September 30, 2025.

16% of revenue by location of the customer in H1 2026 (H1 2025: 19%) was attributable to customers in the US and 7% (H1 2025: 7%) to customers in Germany. Switzerland accounted for 43% of revenue by location of the company (H1 2025: 42%), the US accounted for 12% (H1 2025: 14%), and Germany for 10% (H1 2025: 9%).

Non-current assets comprise intangible assets, property, plant and equipment, investments accounted for using the equity method, and other non-financial assets. As of the reporting date, 25% was attributable to Switzerland (September 30, 2025: 25%), 23% to Germany (September 30, 2025: 24%) and 20% to Hungary (September 30, 2025: 19%).

In H1 2026, SCHOTT Pharma generated revenue of EUR 50.5m with one key customer, which was equivalent to 10.3 % of external revenue. This revenue is derived from the DCS and DDS segments. This customer did not exceed the reportable threshold in the same period of the previous year.

14 Related party disclosures

The group of related companies of SCHOTT Pharma Group includes all direct and indirect subsidiaries, associates and joint ventures of SCHOTT AG, the Carl Zeiss Foundation, Heidenheim an der Brenz and Jena, Carl Zeiss AG, Oberkochen, as well as their related companies (together "Carl Zeiss Group"). No significant transactions were concluded with the Carl Zeiss Foundation or Carl Zeiss Group companies during the reporting period.

In addition, related parties comprise all persons who – as key management personnel – exercise a significant influence on the business activities of SCHOTT Pharma. This includes members of the Management Board of SCHOTT Pharma Management AG, the members of the Supervisory Boards of SCHOTT Pharma KGaA and SCHOTT Pharma Management AG, and their close family members. Please see note 15 for information on the remuneration of individuals in key positions.

Transactions with subsidiaries included in the interim consolidated financial statements of SCHOTT Pharma KGaA were eliminated as part of consolidation and are therefore not explained.

Additional information regarding the group of related parties and the type of business relationships can be found in note 38 of the notes to the consolidated financial statements in the annual report 2025.

Transactions with SCHOTT Group

SCHOTT Pharma Group companies conducted the following transactions with SCHOTT Group companies:

(in EUR k)	H1 2026			H1 2025		
	SCHOTT AG	Remaining SCHOTT companies	Total	SCHOTT AG	Remaining SCHOTT companies	Total
Sale of goods and services and other income	545	3,349	3,894	391	5,096	5,487
Purchase of goods and other expenses for services	50,382	30,981	81,363	52,267	38,921	91,188

Receivables and liabilities related to SCHOTT Group companies are as follows:

(in EUR k)	Mar. 31, 2026			Sep. 30, 2025		
	SCHOTT AG	Remaining SCHOTT companies	Total	SCHOTT AG	Remaining SCHOTT companies	Total
Receivables	169,819	1,674	171,493	159,705	1,493	161,198
thereof trade receivables	4,002	1,674	5,676	4,602	1,493	6,095
thereof from financing	165,817	0	165,817	155,103	0	155,103
Liabilities	224,380	21,750	246,130	229,962	20,565	250,527
thereof trade liabilities	11,329	10,667	21,996	19,129	11,445	30,574
thereof from financing	213,051	11,083	224,134	210,833	9,120	219,953

As of March 31, 2026, loss allowances for receivables in relation to SCHOTT Group companies were recorded in the amount of EUR 1k (September 30, 2025: EUR 1k).

As of September 30, 2025, there were also other financial assets for reimbursement claims against a company of the SCHOTT Group in the amount of EUR 684k arising from renovation on a leased production building.

Financing

The SCHOTT Pharma companies are included in SCHOTT Group's cash pooling and treasury management. Financial receivables and liabilities relate essentially to cash pooling transactions. The balances are interest-bearing with interest rates having been agreed on an arm's length basis. The interest rate is determined based on the arm's length principle using the respective currency-specific monthly reference interest rate (for example, 1M Euribor) plus a margin.

In connection with cash pooling and treasury management, the SCHOTT Group granted several revolving credit facilities to SCHOTT Pharma companies totaling EUR 412m (September 30 2025: EUR 412m). The term of these credit facilities ends on December 31, 2027. As part of cash pooling and treasury management, EUR 224m (September 30, 2025: EUR 220m) was drawn as of March 31, 2026.

Interest income in connection with the transactions amounted to EUR 2,840k in H1 2026 (H1 2025: EUR 3,100k), of which EUR 2,840k (H1 2025: EUR 3,100k) is attributable to SCHOTT AG, whereas interest expenses in H1 2026 amounted to EUR 3,715k (H1 2025: EUR 6.173k), of which EUR 3,602k (H1 2025: EUR 6,133k) is attributable to SCHOTT AG.

Hedging

Any hedging activities for SCHOTT Pharma are performed on an arm's length basis via SCHOTT AG. Remuneration is in line with prevailing market terms.

Leases

The following table presents the development of right-of-use assets related to SCHOTT Group companies:

(in EUR k)	H1 2026	H1 2025
Oct. 1	63,532	67,505
Depreciation, amortization and impairment	-1,921	-1,923
Foreign currency translation	47	93
March 31	61,658	65,675

The following table presents the development of lease liabilities related to SCHOTT Group companies:

(in EUR k)	H1 2026	H1 2025
Oct. 1	68,798	71,246
Repayment and interest	-1,220	-1,138
Foreign currency translation	48	93
March 31	67,626	70,201

Transactions with associates and joint ventures

SCHOTT Pharma Group companies conducted the following transactions with joint ventures:

(in EUR k)	H1 2026	H1 2025
Sale of goods and services and other income	1,740	1,057
Purchase of goods and other expenses for services	1,720	643

Receivables and liabilities in relation to joint ventures are as follows:

(in EUR k)	Mar. 31, 2026	Sep. 30, 2025
Receivables	1,366	698
Liabilities	0	428

As of March 31, 2026, loss allowances for receivables from joint ventures were recorded in the amount of EUR 54k (September 30, 2025: EUR 58k).

There were no material transactions with associates during the reporting periods. There were also no receivables or liabilities on the respective reporting dates.

15 Remuneration of the Management Board and the Supervisory Board

In accordance with IAS 24.17, remuneration for the Management Board of SCHOTT Pharma Management AG, general partner of SCHOTT Pharma KGaA, is as follows:

(in EUR k)	H1 2026	H1 2025
Short-term benefits	807	621
Share-based remuneration	153	112
Total remuneration	960	732

The remuneration of the members of the Supervisory Board of SCHOTT Pharma KGaA, which consisted exclusively of payments due in the short-term, comprised a base remuneration as well as additional remuneration for committee work and amounted to EUR 162k in H1 2026 (H1 2025: EUR 165k).

The remuneration of the members of the Supervisory Board of SCHOTT Pharma Management AG, which consisted exclusively of payments due in the short-term, comprised only a base remuneration and amounted to EUR 40k in H1 2026 (H1 2025: EUR 37k).

Additional information can be found in note 39 of the notes to the consolidated financial statements in the annual report 2025 and in the remuneration report for the financial year 2025.

16 Events after the reporting date

No other significant events occurred between the reporting date (March 31, 2026) and the preparation date (May 8, 2026) that would have a material impact on SCHOTT Pharma Group's net assets, financial position and results of operations.

Mainz, May 8, 2026

SCHOTT Pharma AG & Co. KGaA
Represented by the Management Board of SCHOTT Pharma Management AG

Dr. Christian Mias

Reinhard Mayer

Additional information

Responsibility statement

To the best of our knowledge and in accordance with the financial reporting principles applicable to interim reporting, the interim consolidated financial statements of SCHOTT Pharma AG & Co. KGaA give a true and fair view of the net assets, financial position, and results of operations of the Group, and the interim Group management report includes a fair review of the development and performance of the business and the position of the Group, together with a description of the material opportunities and risks associated with the expected development of the Group in the remainder of the financial year.

Mainz, May 8, 2026

SCHOTT Pharma AG & Co. KGaA
Represented by the Management Board of SCHOTT Pharma Management AG

Dr. Christian Mias

Reinhard Mayer

Review report

To SCHOTT Pharma AG & Co. KGaA

We have reviewed the Condensed Interim Consolidated Financial Statements of the SCHOTT Pharma AG & Co. KGaA, Mainz – comprising the Consolidated Statement of Income, Consolidated Statement of Comprehensive Income, Consolidated Statement of Financial Position, Consolidated Statement of Cash Flows, Consolidated Statement of Changes in Equity and Notes to the Condensed Interim Consolidated Financial Statements – together with the Interim Group Management Report of the SCHOTT Pharma AG & Co. KGaA, Mainz, for the period from October 1, 2025 to March 31, 2026 that are part of the semi annual financial report according to § 115 WpHG [“Wertpapierhandelsgesetz”: “German Securities Trading Act”]. The preparation of the condensed interim consolidated financial statements in accordance with International Accounting Standard IAS 34 “Interim Financial Reporting” as adopted by the EU, and of the interim group management report in accordance with the requirements of the WpHG applicable to interim group management reports, is the responsibility of the Company’s management. Our responsibility is to issue a report on the condensed interim consolidated financial statements and on the interim group management report based on our review.

We performed our review of the condensed interim consolidated financial statements and the interim group management report in accordance with German generally accepted standards for the review of financial statements promulgated by the Institut der Wirtschaftsprüfer (IDW). Those standards require that we plan and perform the review so that we can preclude through critical evaluation, with a certain level of assurance, that the condensed interim consolidated financial statements have not been prepared, in material respects, in accordance with IAS 34, “Interim Financial Reporting” as adopted by the EU, and that the interim group management report has not been prepared, in material respects, in accordance with the requirements of the WpHG applicable to interim group management reports. A review is limited primarily to inquiries of company employees and analytical assessments and therefore does not provide the assurance attainable in a financial statement audit. Since, in accordance with our engagement, we have not performed a financial statement audit, we cannot issue an auditor’s report.

Based on our review, no matters have come to our attention that cause us to presume that the condensed interim consolidated financial statements have not been prepared, in material respects, in accordance with IAS 34, “Interim Financial Reporting” as adopted by the EU, or that the interim group management report has not been prepared, in material respects, in accordance with the requirements of the WpHG applicable to interim group management reports.

Frankfurt am Main, May 8, 2026

KPMG AG
Wirtschaftsprüfungsgesellschaft

Forstreuter

Dolibasic

Wirtschaftsprüfer
[German Public Auditor]

Wirtschaftsprüferin
[German Public Auditor]

Supplementary information

Financial calendar

Date	Event
August 12, 2026	Publication of quarterly statement as of June 30, 2026
December 10, 2026	Publication of annual report 2026

Disclaimer

This half-year financial report contains numerous forward-looking statements which are based on the Company's assumptions, expectations, and intentions. Such statements are indicated by words like "expect", "assume", "intend" or similar wording and are based both on the information currently available to management and on the prevailing environment. These may change at any time. The Company assumes no liability for the ultimate correctness and accuracy of any expectations or assumptions expressed in this report. The Company also undertakes no obligation to update any of its forward-looking statements to bring them in line with actual developments after this half-year financial report has been published.

Due to rounding, individual figures in this document and in other documents may not correspond exactly to the totals stated and percentages shown may not exactly reflect the absolute values to which they relate.

Publication

This half-year financial report was published on May 13, 2026. The document is also available in German. In the event of any discrepancies, the German version shall be authoritative.

Translation: LanguageWire GmbH, Hamburg, Germany

Photography: SCHOTT AG

Imprint and contact

SCHOTT Pharma AG & Co. KGaA

Hattenbergstraße 10

55122 Mainz, Germany

Tobias Erfurth

Head of Investor Relations

Website: www.schott-pharma.com

Email: ir.pharma@schott.com